SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
__________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 30, 1998
-------------------
THE FEMALE HEALTH COMPANY
---------------------------
(Exact Name of Registrant as Specified in Charter)
Wisconsin
(State or Other Jurisdiction or Incorporation)
0-18849
(Commission File Number)
919 North Michigan Avenue
Suite 2208
Chicago, Illinois
(Address of Principal Executive Offices)
312-280-2201
(Registrant's telephone number; including area code)
Item 5. Other Events.
On March 30, 1998, The Female Health Company (the "Company") issued the
attached press release announcing it has been awarded an order for 1.2 million
female condoms by the Government of Uganda. Shipments of the female condoms
pursuant to this order will begin and revenues will be received by the Company
in the Company's third fiscal quarter and will continue for a period of three
to six months thereafter.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE FEMALE HEALTH COMPANY
Date: April 6, 1998
BY /s/ O.B. Parrish
----------------------------
O.B. Parrish, Chairman and
Chief Executive Officer<PAGE>
MW2\40266
FEMALE HEALTH
REPORTS ORDER
FOR
1.2 MILLION FEMALE CONDOMS
CHICAGO, March 30, 1998 -- The Female Health Company (AMEX: FHC) reported it
has been awarded an order for 1.2 million female condoms by the Government of
Uganda. The female condoms will be used as a part of the Government's Sexually
Transmitted Infections Project. Shipments will begin in the Company's third
fiscal quarter and be completed prior to the end of the fiscal year.
This order is a part of The Female Health Company's multi-year agreement with
The United Nations Joint Programme on AIDS (UNAIDS), pursuant to which the
Company sells the female condom at a price based on global public sector volume
which is currently set in Sterling at #0.38/unit ($0.64) plus the cost of any
special requirements stipulated by the country.
Results from a UNAIDS supported study released in 1997 showed that when the
female condom was made available as an option, the mean incidence of sexually
transmitted diseases (STDs) decreased by 34% and the number of unprotected sex
acts decreased by 25% compared to when only the male condom was available.
During the last six months, the female condom has been launched in Canada,
Zimbabwe, Zambia, Brazil and Venezuela. It is also marketed in the United
States, United Kingdom, Taiwan, Holland and South Korea. Additional African
countries including Eritrea, Tanzania and Botswana are planning sexually
transmitted disease prevention programs incorporating the availability of the
female condom which the Company believes will result in additional orders.
The Female Health Company, based in Chicago, owns certain worldwide rights to
the female condom, including patents which have been issued in the United
States, United Kingdom, Japan, France, Italy, Germany, Spain, The People's
Republic of China, Canada, New Zealand, South Korea and Australia. The female
condom is the only available product controlled by a woman that protects
against sexually transmitted disease, including HIV/AIDS, and unintended
pregnancy.<PAGE>
